Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

NIHR Health Technology Aassessment is funding a new study looking at the risks and benefits of first line osteoporosis medications (oral bisphosphonates) amongst patients suffering from chronic kidney disease, led by Associate Professor Daniel Prieto-Alhambra of NDORMS.

Load More